A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2006
10/31/2006	US7129356 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
10/31/2006	US7129351 Pyrimido compounds having antiproliferative activity
10/31/2006	US7129349 Methods of synthesizing 3-amino-1,2,4-benzotriazines
10/31/2006	US7129332 Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
10/31/2006	US7129272 Apoptosis inhibitor
10/31/2006	US7129270 Antiinflammatory agents
10/31/2006	US7129261 Cytotoxic agents
10/31/2006	US7129258 Substituted benzoxazoles as estrogenic agents
10/31/2006	US7129253 Compounds
10/31/2006	US7129250 Neuroprotective and anti-proliferative compounds
10/31/2006	US7129247 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
10/31/2006	US7129246 N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
10/31/2006	US7129244 Triazolopyrimidines and related analogs as HSP90-inhibitors
10/31/2006	US7129243 Respiratory system disorders; cardiovascular disorders; antidiabetic agents; antiarthritic agents; antiinflammatory agents; immunosuppressants
10/31/2006	US7129242 Such as 4-((4-chlorophenyl)pyrimidin-2-yl)amino)benzamide; for treatment of inflammation/autoimmune conditions
10/31/2006	US7129241 Pyridazine derivatives
10/31/2006	US7129240 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/31/2006	US7129236 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/31/2006	US7129227 Herpes, hepatitis and aids virus; administering phosphatides
10/31/2006	US7129225 Administering an effective amount of a protein tyrosine kinase inhibitor (containing first and second module) to the patient to protect against or to treat hearing loss
10/31/2006	US7129219 enhance humoral and cell-mediated immune responses to vaccine antigens; 2-deoxy-2-amino- beta -D-glucopyranose (glucosamine) glycosidically linked to an cyclic aminoalkyl (aglycon) group
10/31/2006	US7129207 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders
10/31/2006	US7129077 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder
10/31/2006	US7129073 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
10/31/2006	US7129071 Recombinant methods and materials for producing epothilone and epothilone derivatives
10/31/2006	US7129037 Delivering antigen to dendritic cells by contacting dendritic cells with apopototic cells expressing an antigen to allow antigen to be internalized by the dendritic cells, and wherein apoptotic cells have been induced in vitro to become apoptotic
10/31/2006	US7129034 Culturing stem cell with fibroblast growth factor and epidermal growth factor
10/31/2006	US7128913 Erythropoietin conjugates
10/31/2006	US7128911 Virus-like particle, and an antigen or antigenic determinant of a receptor activator factor kappa beta ligand protein, fragment or peptide
10/31/2006	US7128896 using carbocyanine dyes; photodynamic therapy; in vivo supplying to tumor
10/31/2006	CA2406685C Oxadiazole derivatives having anticancer effects
10/31/2006	CA2333405C Spill resistant pharmaceutical compositions
10/31/2006	CA2332183C Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (egf-r); diagnostic and therapeutic use
10/31/2006	CA2209303C Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
10/31/2006	CA2186508C Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
10/26/2006	WO2006113942A2 Method of inhibiting cathepsin activity
10/26/2006	WO2006113703A2 Carboline derivatives useful in the treatment of cancer
10/26/2006	WO2006113695A1 Combination cancer therapy with bis(thiohydrazide) amide compounds
10/26/2006	WO2006113650A1 Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs
10/26/2006	WO2006113495A2 Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof
10/26/2006	WO2006113483A2 Methods and compositions for treating or preventing cancer
10/26/2006	WO2006113402A1 Methods and compositions for modulating and detecting wisp activity
10/26/2006	WO2006113376A1 2 -aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators
10/26/2006	WO2006113172A1 Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers
10/26/2006	WO2006112556A1 Method for treating cancer using premedication
10/26/2006	WO2006112479A1 Nitrogen-containing heterocyclic compound
10/26/2006	WO2006112477A1 Polyamino acid for use as adjuvant
10/26/2006	WO2006112451A1 Anti-cancer agent comprising protein c inhibitor
10/26/2006	WO2006112435A1 Phosphine transition metal complex, process for producing the same and anticancer drug containing the same
10/26/2006	WO2006112401A1 Composition for treatment of cancer
10/26/2006	WO2006112379A1 Drug for treating or diagnosing vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation
10/26/2006	WO2006112362A1 Process for production of polymer-type therapeutic agent for treatment of cancer
10/26/2006	WO2006112361A1 Polymeric pharmaceutical agent for treatment of cancer and process for production of the same
10/26/2006	WO2006112331A1 Novel condensed pyrrole derivative
10/26/2006	WO2006112330A1 Inhibitory agent for estrone-3-sulfate transporter activity
10/26/2006	WO2006112239A1 hTERT GENE EXPRESSION REGULATORY GENE
10/26/2006	WO2006111783A1 Monosaccharide derivatives as anti-inflammatory and/or anti-cancer agents
10/26/2006	WO2006111759A1 Pyrrolobenzodiazepines
10/26/2006	WO2006111085A1 A method, formulation and use thereor with improved oral absorption of drugs or nutrients
10/26/2006	WO2006111058A1 N4- (substituted oxycarbonyl)-2’,2’-difluoro-2’-deoxycytidines and uses thereof
10/26/2006	WO2006111029A1 Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
10/26/2006	WO2006110931A1 Use of gallium (iii) complexes for treating tumours of the liver
10/26/2006	WO2006084210A9 Hif modulating compounds and methods of use thereof
10/26/2006	WO2006075012A3 Pyrrolodihydroisoquinolines as antiproliferative agents
10/26/2006	WO2006074057A3 Pyrimidine derivatives as kinase modulators and method of use
10/26/2006	WO2006066923A3 Indole derivatives with antitumor activity
10/26/2006	WO2006063707A3 Novel pharmaceutical composition containing at least one dolastatin 10 derivative
10/26/2006	WO2006058869A3 Substituted pteridines for treating inflammatory diseases
10/26/2006	WO2006001035A3 Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof.
10/26/2006	WO2005113534A3 Cxcr1 and cxcr2 chemokine antagonists
10/26/2006	WO2005102301A3 Hydroxymethylbutyrate compositions and uses thereof
10/26/2006	WO2005100363A8 (poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents
10/26/2006	WO2002101008A3 Intracellular signaling molecules
10/26/2006	US20060242716 Disease model animal carrying foreign ppar alpha gene transferred thereinto and use thereof
10/26/2006	US20060241301 Urea derivatives and their use as tyrosinkinase inhibitors
10/26/2006	US20060241284 Transmembrane protein amigo and uses thereof
10/26/2006	US20060241186 Alkylating agent combinations in the treatment of cancer
10/26/2006	US20060241177 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
10/26/2006	US20060241171 Novel physiologically active substances
10/26/2006	US20060241151 Pyrid-2-one derivatives and methods of use
10/26/2006	US20060241138 Heterocyclic amide derivatives for the treatment of diabetes and other diseases
10/26/2006	US20060241131 Pyrrolo[2,3-d]pyrimidine compounds
10/26/2006	US20060241129 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
10/26/2006	US20060241116 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates
10/26/2006	US20060241114 Derivatives of azasugars as anticancer agents
10/26/2006	US20060241112 Kinase inhibitors
10/26/2006	US20060241106 Isoxazole compounds as inhibitors of heat shock proteins
10/26/2006	US20060241099 Use of 2-thia-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
10/26/2006	US20060241090 Administering to a post menopausal woman an effective amount of 2-methylene -19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3
10/26/2006	US20060241087 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
10/26/2006	US20060241051 Metastin derivatives and use thereof
10/26/2006	US20060241028 Respiratory system disorders; lung hypotensive agents; also pituitary adenylate cyclase activating peptide
10/26/2006	US20060240525 Factor VII or VIIa - Like Molecules
10/26/2006	US20060240524 Conjugate comprising polypeptide with N-glycosylation site and sugar; increase blood clot formation for treatment of thrombocytopenia and hemophilia
10/26/2006	US20060240520 monitoring the efficacy of a BAFF-R (a B-cell activating factor belonging to the Tumor Necrosis Factor family) antagonist in the treatment of a disease or disorder associated with aberrant levels of B-cells or B-cell activity
10/26/2006	US20060240519 Novel receptor nucleic acids and polypeptides
10/26/2006	US20060240518 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells
10/26/2006	US20060240517 Novel receptor nucleic acids and polypeptides
10/26/2006	US20060240417 Agent controlling the apoptosis induction by p73
10/26/2006	US20060240414 Genetically engineered glutaminase and its use in antiviral and anticancer therapy

1 ... 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 ... 2211